EUVIMEDEUVIMED entdecken
Open Access

Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration

Alejandro G Szmulewicz iD, Gonzalo Martínez-Alés, Roger Logan, Maria Ferrara, Christian Kelly, Diane Fredrikson, Juan Gago, Sarah Conderino iD, Covadonga M Díaz-Caneja, Joaquín Galvañ, Lorna Thorpe, Vinod Srihari und 7 weitere

American Journal of Epidemiology · 2024

DOI: 10.1093/aje/kwae029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Epidemiology, 2024. Verfasst von Alejandro G Szmulewicz und 18 weiteren Autor:innen. Beteiligte Einrichtung: CAUSALab, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, United States. Hauptthemen laut MEDLINE: Antipsychotic Agents, Psychotic Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, Brain and Behavior Research Foundation, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Good adherence to antipsychotic therapy helps prevent relapses in first-episode psychosis (FEP). We used data from the FEP-CAUSAL Collaboration, an international consortium of observational cohorts, to emulate a target trial comparing antipsychotics, with treatment discontinuation as the primary outcome. Other outcomes included all-cause hospitalization. We benchmarked our results to estimates from the European First Episode Schizophrenia Trial, a randomized trial conducted in the 2000s. We included 1097 patients with a psychotic disorder and less than 2 years since psychosis onset. Inverse-probability weighting was used to control for confounding. The estimated 12-month risks of discontinuation for aripiprazole, first-generation agents, olanzapine, paliperidone, quetiapine, and risperidone were 61.5% (95% CI, 52.5-70.6), 73.5% (95% CI, 60.5-84.9), 76.8% (95% CI, 67.2-85.3), 58.4% (95% CI, 40.4-77.4), 76.5% (95% CI, 62.1-88.5), and 74.4% (95% CI, 67.0-81.2), respectively. Compared with aripiprazole, the 12-month risk differences were -15.3% (95% CI, -30.0 to 0.0) for olanzapine, -12.8% (95% CI, -25.7 to -1.0) for risperidone, and 3.0% (95% CI, -21.5 to 30.8) for paliperidone. The 12-month risks of hospitalization were similar between agents. Our estimates support use of aripiprazole and paliperidone as first-line therapies for FEP. Benchmarking yielded similar results for discontinuation and absolute risks of hospitalization as in the original trial, suggesting that data from the FEP-CAUSAL Collaboration sufficed to remove confounding for these clinical questions. This article is part of a Special Collection on Mental Health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsPsychotic DisordersHumansFemaleMaleAdultAripiprazoleRisperidoneYoung AdultHospitalizationOlanzapineSchizophreniaAdolescentQuetiapine FumarateDrug Monitoring

Stichwörter der Autor:innen

antipsychoticsbenchmarkingcomparative effectivenessfirst-episode psychosispsychotic disordersschizophreniatarget trial emulationtolerability

Substanzen

Antipsychotic AgentsAripiprazoleRisperidoneOlanzapineQuetiapine Fumarate

Autor:innen und Institutionen

  • CAUSALab, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, United States.
  • Department of Psychiatry, Yale School of Medicine, New Haven, CT 06511, United States.
  • Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, United States.
  • Department of Psychiatry, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada.
  • Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine, New York, NY 10016, United States.
  • Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid 280…

ORCID-Profile: Alejandro G Szmulewicz, Sarah Conderino

Förderung

  • NIMH NIH HHS
  • Brain and Behavior Research Foundation
  • NIH

Zitieren

APA

Szmulewicz, A. G., Martínez-Alés, G., Logan, R., Ferrara, M., Kelly, C., Fredrikson, D., Gago, J., Conderino, S., Díaz-Caneja, C. M., Galvañ, J., Thorpe, L., Srihari, V., Yatham, L., Sarpal, D. K., Shinn, A. K., Arango, C., Öngür, D., Hernán, M. A., & Fep-Causal Collaboration, O. B. O. T. (2024). Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwae029

Vancouver

Szmulewicz AG, Martínez-Alés G, Logan R, Ferrara M, Kelly C, Fredrikson D, et al. Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration. American Journal of Epidemiology. 2024. doi:10.1093/aje/kwae029

BibTeX
@article{Szmulewicz2024,
  author = {Szmulewicz, Alejandro G and Martínez-Alés, Gonzalo and Logan, Roger and Ferrara, Maria and Kelly, Christian and Fredrikson, Diane and Gago, Juan and Conderino, Sarah and Díaz-Caneja, Covadonga M and Galvañ, Joaquín and Thorpe, Lorna and Srihari, Vinod and Yatham, Lakshmi and Sarpal, Deepak K and Shinn, Ann K and Arango, Celso and Öngür, Dost and Hernán, Miguel A and Fep-Causal Collaboration, On Behalf Of The},
  title = {Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration},
  journal = {American Journal of Epidemiology},
  year = {2024},
  doi = {10.1093/aje/kwae029}
}
Kostenlos starten →